Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of…

By J. Plana, M. Galderisi, A. Barac, M. Ewer, B. Ky, M. Scherrer-Crosbie, J. Ganame, I. Sebag, D. Agler, L. Badano and 17 more. European Heart Journal-Cardiovascular Imaging, 2014

1,349 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8c9941426c11eb7f1d78d82ebf27ae471721cc32

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, methodology): “Thus, pretreatment evaluation of LV function is required.(173) A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed.”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, methodology): “In general, the cardiovascular concerns can be summarized in categories related to myocardial dysfunction, vascular disease and VHD. 4.1 Myocardial dysfunction Both paediatric and adult survivors of anthracycline-based chemotherapy have a lifelong risk for the development of LV dysfunction and HF.10”
Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. (2018, methodology): “(32) ASE/EACI guideline N/A Cardiotoxic cancer therapy Cardiotoxicity >15% relative reduction from baseline N/A Various”
Myocardial strain imaging: how useful is it in clinical decision making? (2015, methodology): “Modified from Plana et al.43 *The data supporting the initiation of cardioprotection for the treatment of sub-clinical left ventricular dysfunction is limited.”
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol (2016, background): “Although some studies have indicated that echocardiographic indices of diastolic function may detect subclinical changes in cardiac function during cancer treatment, their predictive value remains unproven.(23,25) Moreover, in the oncological setting, changes in diastolic indices such as the E/E′ ra”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, methodology): “For higher-dose anthracyclinecontaining regimens and in patients with high baseline risk, earlier assessment of cardiac function after a cumulative total doxorubicin (or equivalent) dose of 240 mg/m(2) should be considered (see Table 5).(10,31,85) Measurement of at least one cardiac biomarker— high-”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed [173, 174].”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, methodology): “Thus, pretreatment evaluation of LV function is required.(173) A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed.”